CN102482660A - 用于纯化重组adamts13和其它蛋白质的方法以及其组合物 - Google Patents

用于纯化重组adamts13和其它蛋白质的方法以及其组合物 Download PDF

Info

Publication number
CN102482660A
CN102482660A CN2010800370780A CN201080037078A CN102482660A CN 102482660 A CN102482660 A CN 102482660A CN 2010800370780 A CN2010800370780 A CN 2010800370780A CN 201080037078 A CN201080037078 A CN 201080037078A CN 102482660 A CN102482660 A CN 102482660A
Authority
CN
China
Prior art keywords
adamts13
protein
buffer
chromatography
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800370780A
Other languages
English (en)
Chinese (zh)
Inventor
M·哈斯拉赫尔
A·米特雷尔
C·菲德勒
C·迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hundred Deep Co
Hundred Deep LLC
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to CN201710433159.6A priority Critical patent/CN107267490A/zh
Priority to CN201711191958.3A priority patent/CN107988192A/zh
Publication of CN102482660A publication Critical patent/CN102482660A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Sustainable Development (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Water Supply & Treatment (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2010800370780A 2009-07-31 2010-08-02 用于纯化重组adamts13和其它蛋白质的方法以及其组合物 Pending CN102482660A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710433159.6A CN107267490A (zh) 2009-07-31 2010-08-02 用于纯化重组adamts13和其它蛋白质的方法以及其组合物
CN201711191958.3A CN107988192A (zh) 2009-07-31 2010-08-02 用于纯化重组adamts13和其它蛋白质的方法以及其组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23030809P 2009-07-31 2009-07-31
US61/230,308 2009-07-31
PCT/EP2010/061192 WO2011012726A2 (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201710433159.6A Division CN107267490A (zh) 2009-07-31 2010-08-02 用于纯化重组adamts13和其它蛋白质的方法以及其组合物
CN201711191958.3A Division CN107988192A (zh) 2009-07-31 2010-08-02 用于纯化重组adamts13和其它蛋白质的方法以及其组合物

Publications (1)

Publication Number Publication Date
CN102482660A true CN102482660A (zh) 2012-05-30

Family

ID=42588355

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201711191958.3A Pending CN107988192A (zh) 2009-07-31 2010-08-02 用于纯化重组adamts13和其它蛋白质的方法以及其组合物
CN201710433159.6A Pending CN107267490A (zh) 2009-07-31 2010-08-02 用于纯化重组adamts13和其它蛋白质的方法以及其组合物
CN2010800370780A Pending CN102482660A (zh) 2009-07-31 2010-08-02 用于纯化重组adamts13和其它蛋白质的方法以及其组合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201711191958.3A Pending CN107988192A (zh) 2009-07-31 2010-08-02 用于纯化重组adamts13和其它蛋白质的方法以及其组合物
CN201710433159.6A Pending CN107267490A (zh) 2009-07-31 2010-08-02 用于纯化重组adamts13和其它蛋白质的方法以及其组合物

Country Status (22)

Country Link
US (3) US8945895B2 (enExample)
EP (3) EP2459715B1 (enExample)
JP (6) JP5907869B2 (enExample)
KR (7) KR20180087463A (enExample)
CN (3) CN107988192A (enExample)
AU (1) AU2010277491B2 (enExample)
CA (2) CA2769362A1 (enExample)
CO (1) CO6612194A2 (enExample)
DK (1) DK2459715T3 (enExample)
EA (3) EA034292B1 (enExample)
ES (3) ES3039686T3 (enExample)
HR (1) HRP20192303T1 (enExample)
HU (1) HUE046909T2 (enExample)
IN (1) IN2012DN00907A (enExample)
LT (1) LT2459715T (enExample)
MX (2) MX348178B (enExample)
NZ (2) NZ597756A (enExample)
PL (2) PL2459715T3 (enExample)
PT (1) PT2459715T (enExample)
SG (2) SG193855A1 (enExample)
SI (1) SI2459715T1 (enExample)
WO (1) WO2011012726A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640969A (zh) * 2012-06-21 2015-05-20 巴克斯特国际公司 细胞培养基的病毒过滤
CN112126634A (zh) * 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
CN112805298A (zh) * 2018-08-07 2021-05-14 汇恩斯株式会社 制备GLY-Tβ4的方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028605T2 (en) 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
CN103917655B (zh) * 2011-03-14 2016-05-25 康泰伦特药物解决方案有限责任公司 核心蛋白聚糖组合物及其用途
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
EP3102589A1 (en) * 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
MX2019001255A (es) 2016-08-04 2019-05-20 Baxalta Inc Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
WO2019192877A1 (en) * 2018-04-03 2019-10-10 Merck Patent Gmbh Cex chromatography media and low salt elution of target proteins from biopharmaceutical feeds
SG11202110909XA (en) * 2019-04-03 2021-10-28 Genzyme Corp Continuous production of recombinant proteins
US20220339266A1 (en) 2019-10-04 2022-10-27 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US11821000B2 (en) * 2020-11-10 2023-11-21 Dionex Corporation Method of separating viral vectors
WO2023052556A1 (en) * 2021-09-30 2023-04-06 Ichnos Sciences SA Methods of inactivating viral contaminants with a mixture of solvent and detergent
MX2024010855A (es) 2022-03-07 2024-09-11 Takeda Pharmaceuticals Co Produccion cromatografica de afinidad de productos clinicos de inmunoglobulina g (igg) humana.
WO2023219379A1 (ko) * 2022-05-10 2023-11-16 주식회사 녹십자 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물
EP4523680A1 (en) * 2022-05-10 2025-03-19 Green Cross Corporation Novel liquid formulation for plasma protein
US20250334572A1 (en) * 2024-04-26 2025-10-30 Waters Technologies Corporation Host cell protein detection using lateral flow devices

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815873B1 (en) * 1996-06-28 2002-09-11 Bayer Corporation Selective stabilization of proteins by binding to an immobilised affinity ligandduring viral
WO2005099858A1 (en) * 2004-04-13 2005-10-27 Sangart, Inc. Methods and compositions for simultaneously isolating hemoglobin from red blood cells and inactivating viruses
US20060233784A1 (en) * 2001-08-16 2006-10-19 David Ginsburg ADAMTS13 genes and proteins and variants, and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239854A (en) * 1978-04-24 1980-12-16 Sumitomo Chemical Company, Limited Enzyme-immobilization carriers and preparation thereof
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5283182A (en) * 1986-09-17 1994-02-01 Beecham Group Plc Preparation of immobilized hydantoinase stabilized with divalent metal ions
CA1339946C (en) 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
FR2681867B1 (fr) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0629135B1 (en) 1992-03-02 2000-07-26 Bioeng, Inc. Viral inactivation method
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
GB9503750D0 (en) * 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6429192B1 (en) 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
US6451978B2 (en) * 2000-01-21 2002-09-17 Biovitrum Ab Purification of antithrombin-III-α and β
IL136552A (en) * 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
AU2001294218A1 (en) * 2000-10-11 2002-04-22 Kazusa Dna Research Institute Foundation Novel adamts family polypeptide and gene encoding the same
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CN1230526C (zh) * 2001-02-27 2005-12-07 成都夸常科技有限公司 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法
JP2003144154A (ja) * 2001-11-14 2003-05-20 Mitsubishi Pharma Corp 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子
IL158297A0 (en) * 2001-12-05 2004-05-12 Cangene Corp Pharmaceutical compositions containing immune globulin and methods for the preparation thereof
JP4363986B2 (ja) 2001-12-21 2009-11-11 イミュネックス・コーポレーション タンパク質の精製方法
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
JP3944586B2 (ja) * 2002-10-18 2007-07-11 国立循環器病センター総長 フォンビルブランド因子切断酵素の特異的基質および活性測定法
DE602004029058D1 (de) 2003-07-09 2010-10-21 Shinonogi & Co Ltd Inducer von atopischer dermatitis
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
EP2277912B1 (en) 2004-06-07 2016-09-28 Therapure Biopharma Inc. Isolation of plasma proteins
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7515392B2 (en) 2004-07-28 2009-04-07 Texas Instruments Incorporated High voltage circuits implemented using low voltage transistors
DE102004044419B4 (de) * 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
JP2006083044A (ja) 2004-09-17 2006-03-30 Hitachi Ltd ガラス部材
WO2006072579A1 (en) * 2005-01-05 2006-07-13 Foundation For Fatal Rare Disease Pharmaceutically active antiviral peptides
US20060193966A1 (en) * 2005-02-28 2006-08-31 Shaowen Wu Multi-anion treated soy proteins and methods for preparation thereof
AU2006257073B2 (en) 2005-06-17 2011-08-04 Children's Medical Center Corporation ADAMTS13-comprising compositions having thrombolytic activity
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
US7506514B2 (en) 2005-06-30 2009-03-24 United Technologies Corporation Augmentor fuel conduit bushing
WO2007065691A2 (en) * 2005-12-07 2007-06-14 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
JP5067917B2 (ja) 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の分離精製方法
EP1990421B1 (en) 2006-02-16 2012-06-13 Mitsubishi Chemical Medience Corporation Method of detecting condition in patient with disturbance of consciousness
US7468258B2 (en) 2006-03-07 2008-12-23 Wake Forest University Health Sciences Self-quenching homofluorophore compositions for detecting enzyme activity
WO2008057074A1 (en) * 2006-11-06 2008-05-15 Millipore Corporation Method of flow-through chromatography
EP1958626B1 (en) 2007-02-13 2014-07-23 Ajinomoto Co., Inc. Method for inactivating viruses by addition of slightly acidic arginine
EP2172544B1 (en) 2007-06-22 2014-11-12 The Chemo-Sero-Therapeutic Research Institute Novel adamts-13 mutant
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
JP5323072B2 (ja) 2007-07-11 2013-10-23 ノボ・ノルデイスク・エー／エス 混合方式又は多様式樹脂を使用する第ｖｉｉｉ因子の精製
WO2009029795A1 (en) * 2007-08-31 2009-03-05 Amgen Inc. Solid-state protein formulation
US20090130714A1 (en) * 2007-09-24 2009-05-21 Reliance Life Sciences Pvt.Ltd. Process for purifying recombinanat tissue plasminogen activator (TPA)
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815873B1 (en) * 1996-06-28 2002-09-11 Bayer Corporation Selective stabilization of proteins by binding to an immobilised affinity ligandduring viral
US20060233784A1 (en) * 2001-08-16 2006-10-19 David Ginsburg ADAMTS13 genes and proteins and variants, and uses thereof
WO2005099858A1 (en) * 2004-04-13 2005-10-27 Sangart, Inc. Methods and compositions for simultaneously isolating hemoglobin from red blood cells and inactivating viruses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
《BLOOD》 20010915 Kazuo Fujikawa et al. Purification of human vonWillebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family 全文 1-22 第98卷, 第6期 *
GALLIA G. LEVY ET AL.: "Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura", 《NATURE》, vol. 413, 31 October 2001 (2001-10-31) *
KAZUO FUJIKAWA ET AL.: "Purification of human vonWillebrand factor–cleaving protease and its identification as a new member of the metalloproteinase family", 《BLOOD》, vol. 98, no. 6, 15 September 2001 (2001-09-15) *
XINGLONG ZHENG ET AL.: "Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》, vol. 276, no. 44, 31 December 2001 (2001-12-31) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640969A (zh) * 2012-06-21 2015-05-20 巴克斯特国际公司 细胞培养基的病毒过滤
CN112126634A (zh) * 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
CN112805298A (zh) * 2018-08-07 2021-05-14 汇恩斯株式会社 制备GLY-Tβ4的方法

Also Published As

Publication number Publication date
ES3039686T3 (en) 2025-10-23
KR101769634B1 (ko) 2017-08-18
LT2459715T (lt) 2020-01-10
AU2010277491A2 (en) 2012-06-21
CA2769362A1 (en) 2011-02-03
EP2459715A2 (en) 2012-06-06
JP5907869B2 (ja) 2016-04-26
EP3211077B1 (en) 2024-09-25
KR101883610B1 (ko) 2018-07-30
PL3211077T3 (pl) 2025-04-14
NZ620988A (en) 2015-07-31
US20150104849A1 (en) 2015-04-16
DK2459715T3 (da) 2020-01-06
WO2011012726A3 (en) 2011-03-31
CN107267490A (zh) 2017-10-20
US20230242897A1 (en) 2023-08-03
EA201270214A1 (ru) 2012-08-30
PT2459715T (pt) 2020-01-09
MX2012001263A (es) 2012-05-22
EA201500952A1 (ru) 2016-05-31
IN2012DN00907A (enExample) 2015-04-03
KR20120053013A (ko) 2012-05-24
AU2010277491A1 (en) 2012-02-16
JP2021004265A (ja) 2021-01-14
JP2018203781A (ja) 2018-12-27
JP2013500711A (ja) 2013-01-10
EP2459715B1 (en) 2019-10-02
EP4299735A2 (en) 2024-01-03
HRP20192303T1 (hr) 2020-10-02
EA023783B1 (ru) 2016-07-29
PL2459715T3 (pl) 2020-04-30
US12492390B2 (en) 2025-12-09
CN107988192A (zh) 2018-05-04
HUE046909T2 (hu) 2020-04-28
JP2016222724A (ja) 2016-12-28
KR20220066435A (ko) 2022-05-24
KR20200146042A (ko) 2020-12-31
KR20180087463A (ko) 2018-08-01
SI2459715T1 (sl) 2020-01-31
SG178175A1 (en) 2012-03-29
JP2015147815A (ja) 2015-08-20
ES2763207T3 (es) 2020-05-27
US8945895B2 (en) 2015-02-03
BR112012002140A2 (pt) 2015-09-15
US20110081700A1 (en) 2011-04-07
KR20170096061A (ko) 2017-08-23
JP6216930B2 (ja) 2017-10-25
EA034292B1 (ru) 2020-01-24
AU2010277491B2 (en) 2015-12-17
EP3211077A1 (en) 2017-08-30
CO6612194A2 (es) 2013-02-01
EP4299735B1 (en) 2025-05-21
NZ597756A (en) 2014-03-28
MX348178B (es) 2017-05-29
US11661593B2 (en) 2023-05-30
CA2916508A1 (en) 2011-02-03
KR20230170815A (ko) 2023-12-19
SG193855A1 (en) 2013-10-30
ES3000382T3 (en) 2025-02-28
KR20190122272A (ko) 2019-10-29
WO2011012726A2 (en) 2011-02-03
EA201992487A1 (ru) 2020-05-31
JP2022171925A (ja) 2022-11-11
EP4299735A3 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
US12492390B2 (en) Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
AU2021200815B2 (en) Methods of purifying recombinant adamts13 and other proteins and compositions thereof
HK1241929A1 (en) Methods of purifying recombinant adamts13 and other proteins and compositions thereof
HK40103492B (en) Methods of purifying recombinant adamts13 and other proteins and compositions thereof
HK40103492A (en) Methods of purifying recombinant adamts13 and other proteins and compositions thereof
HK1241929B (en) Methods of purifying recombinant adamts13 and other proteins and compositions thereof
HK1171784B (en) Method for purifying recombinant adamts13 and other proteins and compositions thereof
HK1171784A (en) Method for purifying recombinant adamts13 and other proteins and compositions thereof
EA049036B1 (ru) Способы очистки рекомбинантного adamts13 и других белков и их композиции

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160819

Address after: Aupu, Switzerland

Applicant after: Hundred deep limited liability company

Applicant after: Hundred deep company

Address before: Aupu, Switzerland

Applicant before: Bakst Helth Co., Ltd.

Applicant before: Baxter International Inc.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120530